

# Adaptive SBRT for Prostate Cancer

Experience with Ethos: Where Prostate SBRT Stands to Gain?

---

C-M Charlie Ma, Ph.D.

Department of Radiation Oncology

FCCC, Philadelphia, PA 19111



# Educational Objectives


---

- **Adaptive radiotherapy (ART) machines**
- **ART workflows and techniques**
- **Fox Chase experience with CBCT-based ART**
- **Preliminary results of adaptive SBRT for prostate**
- **Technical challenges and clinical considerations**

# Adaptive Radiotherapy Systems

## Available ART machines

- ViewRay: MR-linac
- Elekta Unity: MR-linac
- MagnetTx Aurora-RT: MR-linac
- Varian Ethos: CBCT-linac
- Accuray Radixact/Cenos: CBCT-linac
- Elekta Evo: CBCT-linac
- United Imaging: CT-linac
- Akesis/Prowess adaptive workstation: CBCT-linac




# Workflows for IGRT and ART

## Pre-treatment simulation/planning workflow



## IGRT treatment workflow



## ART treatment workflow



Make a  
decision first!



# Questions about Adaptive RT

---

- **Why not to perform ART only for large anatomy changes?**
- **Why are adaptive plans worse than scheduled plans sometimes?**


# An Integrated Workflow for IGRT/ART

---

## Pre-treatment simulation/planning workflow



## Integrated IGRT/ART treatment workflow



# Two Strategies for ART

---

- **Better target localization to reduce the need for ART**

**Dose guided target localization**

- **Better optimization method**

**A two-tier optimization process:**

**1<sup>st</sup> tier: simple DAO optimization - MLC segment shape/weight change**


**2<sup>nd</sup> tier: full optimization - objective function/dose parameter change**

# Dose Guided Localization

---

- **Anatomy (contour) based target localization**

**Large uncertainty due to organ deformation/rotation**




**Contour  
match**

- **Isodose based target localization**

**Improved target coverage and/or OAR sparing:**



**More accurate to enclose the treatment volume**

**Optical avoidance of critical structures**




**Isodose  
match**

# Fractional Dose Distribution



# Anatomy- vs. Isodose-Based Localization



# Two-tier ART Optimization

---

- **1<sup>st</sup> tier: DAO optimization for easy (most) cases**

**Fast optimization by adjusting MLC shape/weight**


- **2<sup>nd</sup> tier: optimization for large (few) anatomy changes**

**Modification of objective function/optimization parameters**


**Better optimization results due to change of solution space**

# Fast Optimization (MLC Shape/Weight)

---




CBCT




Simulation CT

# Full Optimization (New Solution Space)


---



Adaptive plan



Scheduled plan



Reference plan


# Initial ART Experience with Ethos

---

- Ethos ART system installed in Feb 2023
- HyperSight CBCT installed in Sept 2023
- Ethos 2.0 upgrade completed in 2025
- ~ 1000 patients treated with ART
- > 90% ART treatments for SBRT patients



# Imaging Quality Improvement with HyperSight



Rapid imaging in 6.9 seconds (good for breath hold with Identify)

# ART Treatment Sites

---

- Prostate (Varian ARTIA-Prostat NCT05804318 2023, FCCC IIT)
- Cervix (Varian ARTIA-Cervix NCT05197881 2023)
- Bladder/Rectum (FCCC IIT NCT07221058 2025)
- Pancreas/biliary tree (FCCC IIT NCT06984562 2025)
- Oligometas – lymph nodes and bone (FCCC IIT NCT05880667 2023)
- Breast (APBI, FCCC IIT)
- Lung/mediastinum
- Head and neck
- Almost any candidate for SBRT
- Some IMRT patients – prostate bed

# **A Dosimetric Study on Adaptive Prostate SBRT**

---

- **50 prostate cases investigated (250 adaptive fractions)**
- **Workflow/treatment time evaluated**
- **Treatment plans compared (scheduled vs. adaptive)**
- **Typical cases/dosimetric issues analyzed**
- **Challenges and potential gains/improvements**

# Average Time for Each ART Step

Procedure	Description	Average Elapsed time (minute)
Patient Setup	Patient check-in and couch setup	8.42
Segmentation	CBCT, auto-segmentation and physician edits	8.45
Optimization	IMRT optimization and Dose calculation	1.6
Approval	Plan evaluation, approval and Mobius QA	5.75
Treatment	2nd CBCT and dose delivery	8.33

24.1 min


# Clinical Goals for Prostate SBRT

PTV D95%  $\geq 37$  Gy (7.4 Gy/fraction)

Main OARs:


Rectum	Dose Limit (Gy)
Max dose (point)	$\leq 39.3$ Gy
<2cc	$> 37$ Gy
$\leq 10\%$ of rectum	$\geq 33$ Gy
$\leq 20\%$ of rectum	$\geq 30$ Gy
$\leq 50\%$ of rectum	$\geq 18$ Gy

Bladder	Dose Limit (Gy)
Max dose (point)	40.7 Gy
<25% or <50cc (use smaller)	$> 24$ Gy




# Adaptive Plan vs. Scheduled Plan


---



# PTV Coverage – D95%



# Case 1: PTV Coverage/Fraction




OARs met all dose constraints in both adaptive and scheduled plans.

# Case 1: Fraction 5 Geometry Changes

---

CBCT


Simulation CT



Note the changes in rectum/bladder volume and fiducial separation!


# Case 1: Planned vs. Cumulative Dose

---



Planned D95% = 37 Gy vs. cumulative (scheduled) D95 = 35.2 Gy (= 95.1% of D<sub>p</sub>)

# Case 2: PTV Coverage/Fraction




OARs met all dose constraints in both adaptive and scheduled plans.

# Case 2: Fraction 4 Contour Changes

---

CBCT


Simulation CT



Is this a true anatomical change or a contouring variation?


Planning CT	FX 1	FX 2	FX 3	FX 4	FX 5
67.8 cc	72.9 cc	67.8 cc	69.3 cc	87.6 cc	66.3 cc

# Case 2: Target DVH – Scheduled Plan



Target underdosing due to changes in prostate contouring!


# Case 2: Planned vs. Cumulative Dose



Velocity dose summation removed the contouring effect !!!


Planned D95% = 37 Gy vs. cumulative D95 = 36.8 Gy (= 99.5% of Dp)

# OAR Comparison – Rectum




D<sub>max</sub>


D<sub>2cc</sub>




# OAR Comparison – Rectum



D10%



D20%




D50%

# Case 3: Rectal Volume Variation

CBCT


Simulation CT




Rectum appeared larger together with CTV contour changes.

# OAR Comparison – Bladder


$D_{max}$



$D_{25\%}$



$D_{50cc}$




# Case 5: Bladder Volume Variation

---

CBCT


Simulation CT




Bladder appeared smaller and overlapping with target volume.

# Bladder Volume Control Still Necessary?

Whole bladder (solid organ)




Bladder wall




Full bladder is better than empty bladder!

# Further Technical Improvement

Original Ethos plans



Re-normalize dose by 1.6%



Focus on 5-10% fractions with significant anatomical changes!

# Conclusions

---

- **ART is beneficial to patients with large prostate rotation/deformation**
- **Adaptation to changes of anatomy as well as technique/workflow**
- **An integrated IGRT/ART workflow to improve effectiveness/efficiency**

**Acknowledgment to FCCC ART/GU team**

